About re.Mind Capital
re.Mind Capital is a venture capital firm founded in 2020. It is primarily based out of Liverpool, United Kingdom. As of Jan 2024, re.Mind Capital has invested in 13 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series A round of Motif neurotech Overall, re.Mind Capital portfolio has seen 1 IPO and 1 acquisition, namely Neumora and Blackrock Neurotech. A lot of funds co-invest with re.Mind Capital, with names like Palo Santo sharing a substantial percentage of its portfolio. re.Mind Capital has team of 4 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 1 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
re.Mind Capital's List of Top Investments
re.Mind Capital has a portfolio of 13 companies. Their most notable investments are in OpenBCI and CereGate.Their portfolio spans across United States, Germany and Portugal. They have invested in Life Sciences, High Tech, HealthTech and 2 other sectors, across stages such as Series A, Seed and 1 more. Here is the list of top investments by re.Mind Capital:
1. Neumora
Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders. The company has developed Data Biopsy Signatures and Precision Phenotypes technologies by using a data-driven neuroscience platform to design targeted therapies for brain diseases. The product pipeline includes NMRA-140, NMRA-511, and NMRA-094 for depressive disorders, anxiety, sleep, and neurodegenerative disorders.
Key facts about Neumora
- Founded Year: 2020
- Location: Watertown (United States)
- Stage: Public
- Total Funding till date: $612M
- Employee Count: 110 as on May 31, 2026
- Investors: Mubadala, Invus and 18 Others
- Latest Funding Round: Series B, Oct 11, 2022, $*****
- Highlight: Public
Developed of brain-computer interface tool for medical treatment and drug development. The company has developed a next-generation brain computing technology that has the ability to process medicine and computing. The brain implants have features for AI-based computing, device integration, and assessment of neurological illness for medicine development.
Key facts about Precision Neuroscience
Provider of noninvasive neurotechnology and personalized mental healthcare platform. The organization develops and supplies digital therapy systems combined with clinical protocols and training for transcranial magnetic stimulation, neurofeedback, EEG, and related neurological assessment tools. It offers a software-based best practice platform that supports clinicians in delivering individualized care through integrated devices, digital workflows, and therapy monitoring. The platform is deployed in its own network of clinics and licensed to third-party practices.
Key facts about NeuroCare Group
- Founded Year: 2015
- Location: Munich (Germany)
- Stage: Series B
- Total Funding till date: $37M
- Employee Count: 156 as on May 31, 2026
- Investors: Palo Santo, Apeiron Investment Group and 58 Others
- Latest Funding Round: Series B, Feb 05, 2025, $*****
- Highlight: Editors' Pick
4. Synchron
Developer of implantable bioelectronics for the treatment of neurological conditions. The company offers a motor neuroprosthesis the Stentrode which helps paralyzed patients regain the ability to communicate. Also, provides endovascular neuromodulation minimally invasive device that stimulates brain or nerve activity for the treatment of Parkinson’s disease, epilepsy, depression, and others.
Key facts about Synchron
- Founded Year: 2016
- Location: Brooklyn (United States)
- Stage: Series D
- Total Funding till date: $345M
- Employee Count: 126 as on Mar 31, 2026
- Investors: Qatar Investment Authority, Green Sands Equity and 32 Others
- Latest Funding Round: Series D, Nov 06, 2025, $*****
- Highlight: Editors' Pick
Developer of therapeutics for psychiatric and neurological disorders. The company leverages a Biodynamic discovery platform to develop plant-based compounds for CNS disorders. The lead candidates of the company are SENS-01 and SENS-02 for anxiety, depression, and neurological disorders.
Key facts about Sensorium Therapeutics
- Founded Year: 2021
- Location: Boston (United States)
- Stage: Series A
- Total Funding till date: $56.8M
- Employee Count: 28 as on May 31, 2026
- Investors: Palo Santo, CU Healthcare Innovation Fund and 8 Others
- Latest Funding Round: Grant (prize money), May 08, 2025, $*****
- Highlight: Editors' Pick
re.Mind Capital's Year-on-Year Investment Trends
re.Mind Capital has invested in 13 companies over the last 5 years, with an average of 2 new investments annually in the last 5 years. Its most recent first time investment was in Motif neurotech.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 1 | 0 | 1 |
2023 | 1 | 0 | 1 |
2022 | 4 | 0 | 4 |
2021 | 7 | 0 | 7 |
re.Mind Capital's Investments by Stage
re.Mind Capital has made 7 investments in Series A stage with an average round size of $91.3M, 3 investments in Seed stage with an average round size of $2M and 3 investments in Series B stage with an average round size of $40.6M.Stage of entry | No. of Investments |
|---|---|
Series A | 7 |
Seed | 3 |
Series B | 3 |
Note: We have considered here, only first round of investments
re.Mind Capital's Investments by Sector
re.Mind Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Consumer, HealthTech and Enterprise Infrastructure. Notably, it has invested in 12 Tech companies, 11 Enterprise (B2B) companies, 5 Tech hardware companies and at least 3 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 10 |
High Tech | 5 |
Consumer | 4 |
HealthTech | 4 |
Enterprise Infrastructure | 1 |
Note: We have considered here, only first round of investments
re.Mind Capital's Investments by Geography
re.Mind Capital has made most investments in United States (10), followed by Germany where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 10 |
Germany | 2 |
Portugal | 1 |
Note: We have considered here, only first round of investments
re.Mind Capital's recent investments
re.Mind Capital has not made any investment in 2026 so far.Here are the most recent investments by re.Mind Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 24, 2024 | United States | Series A | 8289 | [+9] | |
Jan 25, 2023 | United States | Series B | 1382 | ||
Sep 19, 2022 | United States | Series A | 9234 | [+6] | |
Jul 28, 2022 | Portugal | Series A | 9508 | [+7] | |
Mar 08, 2022 | United States | Series A | 5805 | [+2] |
IPOs and Publicly Listed companies in re.Mind Capital's Portfolio
1 of re.Mind Capital's portfolio company became public - Neumora. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2023 at marketcap of $2.58BHere are re.Mind Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 15, 2023 | Oct 07, 2021 | Series A | 4389 |
Acquired companies in re.Mind Capital's Portfolio
1 company from re.Mind Capital's portfolio has been acquired. The most recent acquisition was Blackrock Neurotech in Apr 2024 by Tether for $*****.Here are re.Mind Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 29, 2024 | May 19, 2021 | Series A | 9546 |
Team profile of re.Mind Capital
re.Mind Capital has a team of 4 members including 2 Partners located in United Kingdom. re.Mind Capital's team does not sit on the board of any company as of now.Co-investors of re.Mind Capital
Over the past 5 years, 122 investors have co-invested in re.Mind Capital's portfolio companies. This includes funds and angels.
- Invested before re.Mind Capital: Steadview, B Capital and 12 others have invested in rounds before re.Mind Capital. There is 1 company where Steadview has invested before re.Mind Capital and 1 company where B Capital has invested before re.Mind Capital.
- Top Co-investors of re.Mind Capital: 76 investors entered a company along with re.Mind Capital. These include investors like Palo Santo (4 companies).
- Invested after re.Mind Capital: A total of 32 investors have invested in re.Mind Capital's portfolio after their investments. Top Investors include HHS (3 companies), ADG (1 company) and Exor Ventures (1 company).
Recent News related to re.Mind Capital
•
Motif Neurotech Raises $18.75 Million in Series A Financing to Advance Implantable Device for Treatment-Resistant DepressionBusiness Wire•Jan 24, 2024•Arboretum Ventures, Motif neurotech, KdT Ventures, Satori Capital and 10 others
•
A brain implant no thicker than a human hair: Neuralink’s competitor raises $41M fundingTech Funding News•Jan 26, 2023•B Capital, Steadview, re.Mind Capital, Alumni Ventures and 10 others
•
Digital health specialist set to become “integral part” of £411bn global marketBdaily•Jul 28, 2022•Osram, FLUXUNIT, re.Mind Capital, Alter Venture Partners and 4 others
•
IncrementFi Seed Funding RoundSmartliquidity•Jul 03, 2022•Increment, Dapper Labs, Lattice, Quiet Capital and 7 others
•
OccamzRazor Closes $6.1M Financing RoundFinSMEs•Mar 09, 2022•OccamzRazor, Lauder Partners, re.Mind Capital, Valor Equity Partners
•
Delix Therapeutics Raises $70 MillionGreen Market Report•Sep 27, 2021•Delix Therapeutics, Artis Ventures, RA Capital Management, Apeiron and 14 others
•
Psychedelic alternative realties company scores $11M in Series A fundingMobiHealthNews•Jun 25, 2021•TRIPP, Vine Ventures, Mayfield, Integrated Ventures and 21 others
•
Ksana Health closes $2M seed round to launch advanced mental health monitoring platform and improve patient outcomesTechStartups.com•Jun 16, 2021•Ksana Health, re.Mind Capital, WPSS Investments, Panoramic Ventures and 3 others
•
•
Blackrock Nabs $10 Million to Advance its Brain-Computer Interface (BCI) TechnologyBlackrock Neurotech•May 20, 2021•Blackrock Neurotech, re.Mind Capital, Sorenson Impact
